Table 1.
Characteristics of 66 Pediatric Participants Receiving Isoniazid Preventive Therapy
| Characteristic | Total (n = 66) n (%) | Summary Statistic |
|---|---|---|
| Sex | ||
| Female | 43 (65.1) | |
| Age at Initiation, median (Q1, Q3)1 | 11 (8, 13) | |
| 0–5 years | 6 (9.1) | |
| 6–10 years | 21 (31.8) | |
| 11–15 years | 39 (59.1) | |
| WHO Clinical Staging for HIV at Initiation | ||
| I | 3 (4.5) | |
| II | 26 (39.4) | |
| III | 33 (50.0) | |
| IV | 3 (4.5) | |
| Missing or not reported | 1 (1.5) | |
| History of Tuberculosis | ||
| Yes | 12 (18.2) | |
| No | 54 (81.8) | |
| ART Status | ||
| On ART | 66 (100.0) | |
| Duration of ART at initiation in years, median (Q1, Q3) | 5 (2.25, 8) | |
| History of Liver Disease | ||
| Yes | 0 (0.0) | |
| No | 57 (86.4) | |
| Missing or not reported | 9 (13.6) | |
1(First Quartile, Third Quartile)